Amendment of a drug utilization study protocol based on results from a real-world pilot study of liraglutide use in Europe
Economic and time constraints may incite researchers to avoid formalized pilot studies. Here, we report results of a pilot study that amended the ensuing drug utilization study (DUS) protocol, thus ascertaining fit-for-purpose data availability and quality, to better support regulatory decision-making. This retrospective, multicenter medical chart review in Germany and Italy, 6 months after Saxenda® (liraglutide 3.0 mg, a once-daily human glucagon-like peptide-1 analog for weight management) launch, ahead of a full DUS, collected patient data. The target study population included 100 initiators (25 Saxenda® and 25 Victoza® initiators in both Germany and Italy). Written informed consent was obtained before medical chart data extraction. Overall, 218 sites were contacted, with 39 Saxenda® initiators (33 in Italy; six in Germany) and 52 Victoza® initiators (31 in Italy; 21 in Germany). Patient records were obtained for all enrolled Saxenda® and Victoza® initiators in Italy and Germany; however, availability of individual study variables varied, with follow-up body weight showing the greatest degree of missingness among Saxenda® initiators. The pilot study indicated a poor enrollment feasibility of Saxenda® initiators in Germany and an unfit-for-purpose dose-related data quality. Based on these findings, refinements were implemented in the ensuing DUS protocol to improve the collection of fit-for-purpose real-world data for regulatory decision-making.
Authors
- Jens Aberle (ORCID: https://orcid.org/0000-0002-9360-9442)
- Naveen Rathor
- Paolo Sbraccia (ORCID: https://orcid.org/0000-0001-9634-1501)
- Atheline Major‐Pedersen (ORCID: https://orcid.org/0000-0002-1755-630X)
- Anne Helene Olsen
Institutions
- University of Rome Tor Vergata (IT)
- Universität Hamburg (DE)
- Novo Nordisk (Denmark) (DK)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1038/s41598-026-79385-2
- Citations
- 1
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00